Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07060508 | L9LS in Women of Childbearing Potential in Mali | PHASE2 | RECRUITING | 290 | — | — | Jul 22, 2025 | Apr 1, 2026 | Feb 17, 2026 | 3 | Mali |
Occurring within 7 days after the administration of study agent
Occurring within 7 days after the administration of study agent
Occurring within 14 days after the administration of study agent
Occurring within 14 days after the administration of study agent
| Arm | Type | Description |
|---|---|---|
| L9LS in healthy Malian WOCBP | EXPERIMENTAL | - |
| Placebo in healthy Malian WOCBP | PLACEBO_COMPARATOR | - |
| L9LS in healthy Malian adult males | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Single dose of 1800 mg L9LS SC | BIOLOGICAL | A human monoclonal antibody to protect against Plasmodium falciparum. |
| Placebo | OTHER | Normal saline |
Inclusion Criteria: 1. Females aged ≥18 and ≤49 years and weighing ≥ 45.0 and ≤ 90.0 kg. 2. Males aged ≥18 and ≤49 years (no weight restrictions). 3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 4. In good general health and without...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, Primaquine, Chloroquine, GSK3772701, RTS,S/AS01E vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |